Ligand Pharmaceuticals Inc

Find Ratings Reports
LGND : NASDAQ : Health Care
$127.54 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 234000.0
08/16/17 - 4:00 PM ET

Financial Analysis


LIGAND PHARMACEUTICAL INC's gross profit margin for the second quarter of its fiscal year 2017 has decreased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. LIGAND PHARMACEUTICAL INC has weak liquidity. Currently, the Quick Ratio is 0.82 which shows a lack of ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.

During the same period, stockholders' equity ("net worth") has increased by 12.34% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY17 Q2 FY16
Net Sales ($mil)28.019.52
EBITDA ($mil)0.07.16
EBIT ($mil)13.024.34
Net Income ($mil)6.06-6.17


Balance Sheet Q2 FY17 Q2 FY16
Cash & Equiv. ($mil)172.63106.95
Total Assets ($mil)640.02589.32
Total Debt ($mil)218.63207.36
Equity ($mil)409.41364.44


Profitability Q2 FY17 Q2 FY16
Gross Profit Margin87.1196.98
EBITDA Margin0.036.65
Operating Margin46.4922.24
Sales Turnover0.180.15
Return on Assets1.4134.94
Return on Equity2.2156.3
Debt Q2 FY17 Q2 FY16
Current Ratio0.870.57
Debt/Capital0.350.36
Interest Expense0.03.05
Interest Coverage0.01.42


Share Data Q2 FY17 Q2 FY16
Shares outstanding (mil)21.020.85
Div / share0.00.0
EPS0.26-0.3
Book value / share19.517.48
Institutional Own % n/a n/a
Avg Daily Volume228402.0265700.0

Valuation


BUY. LIGAND PHARMACEUTICAL INC's P/E ratio indicates a significant premium compared to an average of 38.49 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 24.31. To use another comparison, its price-to-book ratio of 6.41 indicates a significant premium versus the S&P 500 average of 3.03 and a significant discount versus the industry average of 10.70. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
LGND 328.89 Peers 38.49   LGND NA Peers 26.75

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

LGND is trading at a significant premium to its peers.

 

Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.

Ratio not available.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
LGND 32.46 Peers 24.79   LGND NM Peers 0.44

Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.

LGND is trading at a significant premium to its peers.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

LGND's negative PEG ratio makes this valuation measure meaningless.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
LGND 6.41 Peers 10.70   LGND -96.02 Peers 10.71

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

LGND is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, LGND is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
LGND 22.41 Peers 152.23   LGND 32.93 Peers 338.91

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

LGND is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

LGND significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades